Curapath has entered into an exclusive license agreement with Calusa Bio, LLC, further strengthening its PEG alternative toolbox with a novel and differentiated technology. This strategic addition enhances our ability to advance PEG-free delivery systems for biologics, peptides, and nucleic acids in next-generation therapies.
By combining Curapath’s expertise in PEG-free excipient development with Calusa Bio’s innovative chemistry platform, we are integrating a cutting-edge solution designed to address the growing demand for safer, less immunogenic delivery technologies.
This collaboration reinforces Curapath’s leadership in providing innovative and accessible formulation strategies to overcome complex challenges in pharmaceutical development. It reflects our continued
commitment to enabling safer and more effective therapies through next-generation excipient technologies.
“Curapath has established itself as a leader in advancing PEG-free excipients and their incorporation into next-generation drug delivery technologies. Calusa Bio is enthusiastic about this partnership and our shared goal of commercializing novel, PEG alternative excipients for broader use in the pharmaceutical drug products.” — Kevin Sill, CEO of Calusa Bio.
About Calusa: Calusa Bio is a biotechnology company dedicated to developing innovative technology to stabilize proteins in biological products. Its focus is on improving the integrity and shelf life of biologic drugs, a key factor in advancing more effective and safer therapies.
About Curapath: Curapath is a global CDMO specialized in the custom design, development, and GMP manufacturing of advanced polymer- and lipid-based drug delivery systems. Our clients benefit from our unique expertise, operational excellence, and technical solutions in nanoparticle-based therapeutics.
